Madrigal pharmaceuticals announces preliminary* fourth-quarter and full-year 2024 net sales, year-end cash and total patients on rezdiffra

Conshohocken, pa., jan. 13, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net sales, year-end cash and patients on rezdiffra.
MDGL Ratings Summary
MDGL Quant Ranking